ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: SA-OR24

Renal Autologous Cell Therapy (REACT) for Type 2 Diabetic Kidney Disease: Preliminary Results with Renal Cortex Implantation

Session Information

Category: Diabetic Kidney Disease

  • 602 Diabetic Kidney Disease: Clinical


  • Stavas, Joseph, ProKidney, Raleigh, North Carolina, United States
  • Ferris, Maria E., University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, United States
  • Silva, Arnold L., Boise Kidney and Hypertension, Boise, Idaho, United States
  • Detwiler, Randal K., University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, United States
  • Coca, Steven G., Icahn School of Medicine at Mount Sinai, New York, New York, United States
  • Burgner, Anna Marie, Vanderbilt University School of Medicine, Nashville, Tennessee, United States
  • Segal, Mark S., University of Florida College of Medicine, Gainesville, Florida, United States
  • Thajudeen, Bijin, Banner University Medical Center Tuscon, Tucson, Arizona, United States
  • Filler, Guido, Western University, London, Ontario, Canada
  • Bakris, George L., The University of Chicago Medicine, Chicago, Illinois, United States

Diabetic Kidney Disease (DKD) is the leading cause of kidney failure in the United States. REACT in preclinical trials demonstrated stability and improved kidney function without adverse effects. We present the 12 month findings of an ongoing Phase II multicenter randomized clinical trial (RCT) evaluating autologous homologous cell therapy on DKD progression in patients with stages 3a-4 DKD.


In this open label 1:1 RCT, 83 participants, 30-80 yrs, eGFR 20-50 ml/min/1.73m2 were randomized to either REACT or a control group of standard of care. All patients had a kidney biopsy with renal progenitor cell isolation and expansion by cGMP. The treated group received two cell implants into the kidney cortex at six-month intervals with CT guidance. The control received standard of care treatment (SoC) including maximized hypertension, diabetes and comorbidity management. The primary endpoint is change in eGFR. The current analysis compares the mean eGFR and UACR of completers in each group at 12 months.


No differences in Hgb or HbA1c were present between groups at baseline or 12 months. Annualized mean eGFR increased and UACR decreased in the treatment group from time of first injection to 12 months (Table). Major bleeding complications occurred in 1% of each group following biopsy or cell injections. There were no cell-related adverse events.


Preliminary findings indicate implantation of progenitor REACT into the renal cortex in DKD is safe and improved annualized eGFR and UACR. Further data will follow completion of the study.

Screening DataTreatedControlp value
Age (yrs)65.6±1.564.5±1.40.61
Gender % (male)71.463.4 
Caucasian %90.573.2
African American %4.812.2
Hemoglobin g/dL12.7±0.312.5±0.20.63
HbA1c %7.2±0.27.1±0.20.59
eGFR min/mL/1.73m234.2±1.331.48±1.30.67
UACR (mg/gm)1143±29.41621±87.50.48
12-month AnalysisTreatedControlp value

All Data: Mean ± Standard Error


  • Commercial Support